MAY 0 8 2002 &



Patent Application Attorney Docket No. PC10139AMAG

11/C 4/21/02 (

here besertify that this correspondence is being deposited with the United States Postal Service as first-class mail in an analysis addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 1st day of May 2002.

Ву _____

(Signature of person mailing)

Kelley D. Surprenant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Typed or printed name of person)

RECEIVED

MAY 1 3 2002

TECH CENTER 1600/2900

IN RE APPLICATION OF:

N. HARPER ET AL.

Examiner: T. OH

APPLICATION NO.: 09/417,175

Group Art Unit: 1623

FILING DATE: OCTOBER 11, 1999

TITLE: SERTRALINE ORAL CONCENTRATE

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

REPLY AND AMENDMENT UNDER 37 C.F.R. 1.111 AND 1.121

In response to the Office Action dated November 6, 2001, Applicants make the following amendments and remarks. The period for response to the Office Action has been extended to May 6, 2002, pursuant to Applicants' Petition for Extension of Time filed herewith.

IN THE CLAIMS:

Please amend claim 8 to read as follows:

8. (Amended) The composition of claim 7 wherein the flavoring agents are selected from the group consisting of peppermint, spearmint and menthol; and wherein the preservatives are selected from the group consisting of butylhydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cysteine, ethylenediamine tetraacetic acid or salts thereof, citric acid, triethanolamine, thioglycerol, methylparaben and propylparaben.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Claims 1, 7-12 and 14-19 are pending in the present application. These claims have been rejected.

With respect to the Election/Restriction requirement, Applicants appreciate the Examiner's reconsideration of this requirement and the rejoinder of groups I and II.

 C_{\prime}